Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7560277 | 0.99 | OPRM1 (0.42) | OPRM1CYP3A4TSHRABCB11LMNA | |
| SCHEMBL3465278 | 0.89 | TSHR (0.42) | CYP3A4TSHRABCB11LMNACYP1A2 | |
| SCHEMBL1684100 | 0.89 | OPRM1 (0.48) | OPRM1CYP3A4TSHRABCB11LMNA | |
| Hydrochloric Acid SCHEMBL1282252 | 0.88 | OPRM1 (0.47) | OPRM1CYP3A4TSHRABCB11LMNA | |
| SCHEMBL1311224 | 0.85 | CYP3A4 (0.52) | OPRM1CYP3A4TSHRABCB11LMNA | |
| SCHEMBL2007741 | 0.84 | OPRM1 (0.45) | OPRM1CYP3A4TSHRABCB11LMNA | |
| Hydrochloric Acid SCHEMBL5729678 | 0.84 | CYP3A4 (0.53) | OPRM1CYP3A4TSHRABCB11LMNA | |
| Hydrochloric Acid SCHEMBL19410760 | 0.83 | CYP3A4 (0.44) | OPRM1CYP3A4TSHRABCB11LMNA | |
| SCHEMBL1976918 | 0.81 | CYP3A4 (0.48) | OPRM1CYP3A4TSHRABCB11LMNA | |
| SCHEMBL2925260 | 0.81 | CYP3A4 (0.51) | OPRM1CYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-1187614-A4 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MERCK & CO., INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1187614-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6350760-B1 | OBESITY, DIABETES, SEXUAL DYSFUNCTION; | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| WO-2000074679-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | OPRM1 86/4885CYP3A4 1106/4885TSHR 342/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | OPRM1 4448/4885CYP3A4 4516/4885TSHR 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.